相关文章
Stephenson Harwood advises Premji Invest and TPG NewQuest on partial exit from iD Fresh Foods
了解更多
Stephenson Harwood advises on Kester Capital acquisition and MBI of EMAS Pharma
Law firm Stephenson Harwood LLP has advised the management team of EMAS Pharma on Kester Capital's acquisition of EMAS Pharma.
The transaction included a platform management buy-in for the management team, all of whom have experience in private equity-backed clinical research organisations.
Kester Capital is a UK private equity investor, focused on the technology & healthcare sectors. EMAS Pharma is a leading clinical research organisation, providing specialised services to the global pharmaceutical and biotech sectors across multiple therapeutic areas, including oncology, rare diseases, inflammation, immunology and microbiome therapeutics.
The investment from Kester and the incoming management team will enable EMAS Pharma to expand its range of service capabilities, enhance its technology base, and strengthen its presence in global markets, including North America and Europe.
The Stephenson Harwood team was led by private equity partner Chris Manning, supported by managing associate Alex Stevens and associate Jessica Martin. Further support was provided by employment partner Richard Freedman and associate Dermot Neligan.